AtaiBeckley股东批准礼来收购，预计2026年9月11日完成交割

----- ef20081508_8k.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 8, 2026
ATAIBECKLEY INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
001-43037
41-3357923
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
c/o atai Life Sciences US, Inc. c/o Industrious NYC, 250 West 34th Street
New York
,
New York
10119
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (
332
)
282-0507
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.01 par value per share
ATAI
The Nasdaq Stock Market LLC
(Nasdaq Global Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.07
Submission of Matters to a Vote of Security Holders
On September 8, 2026, AtaiBeckley Inc., a Delaware corporation (“AtaiBeckley”), held a virtual special meeting of its stockholders (the “Special Meeting”) to vote on the proposals identified in the definitive proxy statement of AtaiBeckley prepared in connection with the Merger Agreement (as defined below) filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 10, 2026, which was first mailed to the AtaiBeckley stockholders on August 10, 2026.
As of the close of business on August 7, 2026, the record date for the Special Meeting, there were 370,864,669 shares of common stock, par value $0.01 per share, of AtaiBeckley (“AtaiBeckley Common Stock”) issued and outstanding and entitled to vote at the Special Meeting. At the Special Meeting, a total of 243,351,557 shares of AtaiBeckley Common Stock, representing approximately 65.6% of all of the shares of issued and outstanding AtaiBeckley Common Stock entitled to vote, were present in person (virtually) or represented by proxy at the Special Meeting and thus a quorum was present. The tables below detail the final voting results for each proposal.
1.
Proposal No. 1 - The Merger Proposal
: To approve the adoption of the Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”), dated as of July 15, 2026, by and among Eli Lilly and Company, an Indiana corporation (“Lilly”), Albali Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly, and AtaiBeckley (the “Merger Proposal”).
The Merger Proposal was approved by the requisite vote of AtaiBeckley’s stockholders.
Votes For
Votes Against
Abstentions
237,762,253
5,033,755
555,549
2.
Proposal No. 2 - The Adjournment Proposal
: To approve any proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve the Merger Proposal at the time of the Special Meeting (the “Adjournment Proposal”).
The Adjournment Proposal was approved
by the requisite vote of AtaiBeckley’s stockholders.
Votes For
Votes Against
Abstentions
229,411,340
12,814,164
1,126,053
As
the Merger Proposal was approved, the Adjournment Proposal was not acted upon.
Assuming the satisfaction or waiver of all the other conditions to the merger, AtaiBeckley expects that the merger will be consummated on September 11, 2026.
Forward-Looking Statements
This Current Report on Form 8-K (this “Report”) contains
forward-looking statements that involve substantial risks and uncertainties,
including statements regarding the pending merger and the timing of closing.
All statements other than statements of historical facts are forward-looking
statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “will,” “would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements are based on current
beliefs and expectations, and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in, or implied by, such forward-looking
statements. These risks and uncertainties include, but are not limited to: a
failure to (or delay in) receiving the required regulatory clearances for the
merger; a condition to closing of the merger may not be satisfied (or waived);
the ability of each party to consummate the merger; the closing of the merger
might be delayed or not occur at all; the occurrence of any event, change or
other circumstance that could give rise to the termination of the Merger
Agreement; the diversion of management time and attention from ongoing business
operations and opportunities; the response of competitors to the merger; the
effect of the merger and the public announcement of the merger on AtaiBeckley's
operations and its relationships with its suppliers, business partners,
management and employees, including its ability to attract and retain key
personnel; Lilly's ability to successfully integrate AtaiBeckley and execute on
the continued development of AtaiBeckley's programs following the closing of
the merger; that all or any of the potential milestone payments pursuant to the
contingent value rights will not become payable on the terms described in the
Merger Agreement or at all; the outcome of any legal proceedings that could be
instituted against the parties to the merger; the risks inherent in drug
research, development and commercialization; disruption in AtaiBeckley's plans
and operations attributable to the merger; changes in AtaiBeckley's business
during the period between announcement and closing of the merger; Lilly's
evaluation of the accounting treatment of the potential acquisition and its
potential impact on its financial results and financial guidance; the effects
of the merger on AtaiBeckley's stock price; relationships with key third
parties or governmental entities; regulatory changes and developments; and the
impact of global macroeconomic conditions, including trade and other global
disputes and interruptions, including related to tariffs, trade protection
measures, and similar restrictions. For further discussion of these and other
risks and uncertainties, see AtaiBeckley's definitive proxy statement filed
with the SEC on August 10, 2026 and AtaiBeckley's periodic reports filed with
the SEC. There can be no assurance that the merger will in fact be consummated.
All forward-looking statements in this Report are based on information
available to AtaiBeckley as of the date hereof. AtaiBeckley expressly disclaims
any obligation to publicly update or revise the forward-looking statements,
except as required by law.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 8, 2026
ATAIBECKLEY INC.
By:
/s/ Srinivas Rao
Name:
Srinivas Rao
Title:
Chief Executive Officer